Jim Simons Biotechnology

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
VTYX Ventyx Biosciences, Inc.	$106M	$683,000 0.0% of portfolio	313,700	Q3 2024 New
CRTX Cortexyme, Inc.	$70.5M	$674,000 0.0% of portfolio	522,576	Q3 2024 Added 7.99%
ACHL Achilles Therapeutics PLC	$56.7M	$650,000 0.0% of portfolio	638,133	Q3 2024 Reduced 6.53%
IMUX Immunic, Inc.	$29.3M	$641,000 0.0% of portfolio	389,081	Q3 2024 Added 33.66%
ALVR Allovir, Inc.	$912M	$629,000 0.0% of portfolio	776,857	Q3 2024 Reduced 1.81%
TARA Protara Therapeutics, Inc.	$55.4M	$616,000 0.0% of portfolio	336,740	Q3 2024 Added 123.9%
ORMP Oramed Pharmaceuticals Inc.	$83.9M	$598,000 0.0% of portfolio	245,300	Q3 2024 Added 6.28%
RAPT Rapt Therapeutics, Inc.	$33.8M	$592,000 0.0% of portfolio	294,600	Q3 2024 Added 44.48%
PYXS Pyxis Oncology, Inc.	$56.9M	$588,000 0.0% of portfolio	160,336	Q3 2024 Added 65.4%
CSBR Champions Oncology, Inc.	$140M	$584,000 0.0% of portfolio	119,991	Q3 2024 Reduced 2.12%
OMGA Omega Therapeutics, Inc.	$23M	$579,000 0.0% of portfolio	474,600	Q3 2024 Added 269.63%
ALDX Aldeyra Therapeutics, Inc.	$302M	$578,000 0.0% of portfolio	107,400	Q3 2024 Reduced 78.66%
INMB Inmune Bio, Inc.	$174M	$577,000 0.0% of portfolio	107,200	Q3 2024 New
NXTC Next Cure, Inc.	$22.5M	$556,000 0.0% of portfolio	406,000	Q3 2024 Reduced 12.15%
BLUE Bluebird Bio, Inc.	$542M	$550,000 0.0% of portfolio	1,058,172	Q3 2024 Added 33.69%
CDMO Avid Bioservices, Inc.	$776M	$547,000 0.0% of portfolio	48,124	Q3 2024 New
ICCC Immucell Corp	$41.3M	$542,000 0.0% of portfolio	149,489	Q3 2024 Added 19.03%
VOR Vor Biopharma Inc.	$51M	$529,000 0.0% of portfolio	756,011	Q3 2024 Added 52.64%
ETON Eton Pharmaceuticals, Inc.	$442M	$500,000 0.0% of portfolio	83,400	Q3 2024 Reduced 21.69%
RLYB Rallybio Corp	$28M	$472,000 0.0% of portfolio	403,700	Q3 2024 Added 18.49%
ALLK Allakos Inc.	$20.3M	$471,000 0.0% of portfolio	725,839	Q3 2024 Added 29.06%
GLSI Greenwich Life Sciences, Inc.	$164M	$467,000 0.0% of portfolio	32,500	Q3 2024 Reduced 11.92%
ANTX An2 Therapeutics, Inc.	$22.1M	$453,000 0.0% of portfolio	423,800	Q3 2024 Added 2,863.64%
CHRS Coherus Bio Sciences, Inc.	$86.3M	$449,000 0.0% of portfolio	432,068	Q3 2024 Added 9.43%
NAUT Nautilus Biotechnology, Inc.	$213M	$440,000 0.0% of portfolio	154,700	Q3 2024 Added 10.42%
ATXS Astria Therapeutics, Inc.	$119M	$419,000 0.0% of portfolio	38,061	Q3 2024 Added 69.45%
NERV Minerva Neurosciences, Inc.	$11.8M	$419,000 0.0% of portfolio	157,200	Q3 2024 Reduced 6.26%
CMPX Compass Therapeutics, Inc.	$312M	$409,000 0.0% of portfolio	222,600	Q3 2024 Added 58.32%
PRLD Prelude Therapeutics Inc	$40.4M	$407,000 0.0% of portfolio	196,900	Q3 2024 Reduced 4.7%
MNOV Medicinova Inc	$94.2M	$391,000 0.0% of portfolio	186,600	Q3 2024 Reduced 11.14%
TCRX T Scan Therapeutics, Inc.	$49.4M	$368,000 0.0% of portfolio	74,000	Q3 2024 Reduced 7.5%
YMAB Y M Abs Therapeutics, Inc.	$254M	$366,000 0.0% of portfolio	27,900	Q3 2024 Reduced 56.84%
OLMA Olema Pharmaceuticals, Inc.	$241M	$351,000 0.0% of portfolio	29,400	Q3 2024 Reduced 44.74%
ELYM Eliem Therapeutics, Inc.	$109M	$349,000 0.0% of portfolio	68,600	Q3 2024 Added 85.41%
CARA Cara Therapeutics, Inc.	$257M	$343,000 0.0% of portfolio	1,108,931	Q3 2024 Added 4.05%
ELDN Eledon Pharmaceuticals, Inc.	$62.2M	$338,000 0.0% of portfolio	135,873	Q3 2024 Reduced 0.66%
HOWL Werewolf Therapeutics, Inc.	$41M	$322,000 0.0% of portfolio	152,200	Q3 2024 Reduced 10.99%
LTRN Lantern Pharma Inc.	$55.9M	$308,000 0.0% of portfolio	84,000	Q3 2024 Added 2.69%
FGEN Fibrogen Inc	$45M	$301,000 0.0% of portfolio	753,140	Q3 2024 New
LGND Ligand Pharmaceuticals Inc	$1.94B	$300,000 0.0% of portfolio	3,000	Q3 2024 Reduced 83.52%
SPRB Spruce Biosciences, Inc.	$8.95M	$286,000 0.0% of portfolio	609,700	Q3 2024 Added 66.54%
ALXO Alx Oncology Holdings Inc	$53.8M	$282,000 0.0% of portfolio	155,300	Q3 2024 Reduced 64.56%
LYEL Lyell Immunopharma, Inc.	$144M	$272,000 0.0% of portfolio	197,400	Q3 2024 Added 29.61%
SCPH Sc Pharmaceuticals Inc.	$88M	$267,000 0.0% of portfolio	58,656	Q3 2024 Reduced 73.46%
EQ Equillium, Inc.	$23M	$266,000 0.0% of portfolio	321,173	Q3 2024 Added 6.92%
CNTB Connect Biopharma Holdings LTD	$53.4M	$252,000 0.0% of portfolio	175,500	Q3 2024 Reduced 17.33%
SILO Silo Pharma, Inc.	$5.05M	$249,000 0.0% of portfolio	227,006	Q3 2024 New
ATNM Actinium Pharmaceuticals, Inc.	$30.2M	$238,000 0.0% of portfolio	127,000	Q3 2024 Added 561.46%
TRVI Trevi Therapeutics, Inc.	$229M	$236,000 0.0% of portfolio	70,700	Q3 2024 Added 36.22%
FHTX Foghorn Therapeutics Inc.	$166M	$234,000 0.0% of portfolio	25,236	Q3 2024 Added 135.85%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account